The short version of anti-doping analysis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-20 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
=== COVID-19 pandemic === Bukele issued an executive decree on 11 March 2020 imposing a "quarantine throughout the national territory" ("cuarentena en todo el territorio nacional"), shortly after World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus declared the COVID-19 outbreak a pandemic. The quarantine suspended all school activities for 21 days, prohibited foreigners from entering the country, and mandated a 30-day quarantine for everyone entering the country. Bukele confirmed the first case of COVID-19 in El Salvador on 18 March 2020. The country's first death from the disease was recorded on 31 March. On 5 May 2023, the Pan American Health Organization declared the end of the pandemic. According to the WHO, As of 27 September 2023, El Salvador had 201,807 confirmed cases of COVID-19 and 4,230 deaths from the disease by 2 June 2023; the WHO reported that 11,426,688 doses of the COVID-19 vaccine had been administered in El Salvador by that date.
=== Simmons === Dr. Simmons is a Black Mesa scientist. He is seen in Half-Life: Blue Shift. In Blue Shift, Dr. Simmons is seen fixing a battery in Dr. Rosenberg's office, along with Dr. Walter Bennett. The three scientists soon get it fixed with the help of Barney Calhoun, and they start their teleportation out of Black Mesa. The four successfully make it out of the facility, making Dr. Simmons one of the few known survivors of the incident. They open the gates and start their journey to the outside world with an SUV. Simmons does not talk at all in the game, and his first name is unknown. Furthermore, his final fate is unknown like all of his colleagues.
==== Delta (δ) notation ==== Isotope ratios for a substance are often reported compared to a standard with known isotopic composition, and measurements of relative masses are always made in conjuncture with measuring a standard. For hydrogen, the Vienna Standard Mean Ocean Water standard is used which has an isotope ratio of 155.76±0.1 ppm. The delta value as compared to this standard is defined as:
The diploid nature of chromosomes allows for genes on different chromosomes to assort independently or be separated from their homologous pair during sexual reproduction wherein haploid gametes are formed. In this way new combinations of genes can occur in the offspring of a mating pair. Genes on the same chromosome would theoretically never recombine. However, they do, via the cellular process of chromosomal crossover. During crossover, chromosomes exchange stretches of DNA, effectively shuffling the gene alleles between the chromosomes. This process of chromosomal crossover generally occurs during meiosis, a series of cell divisions that creates haploid cells. Meiotic recombination, particularly in microbial eukaryotes, appears to serve the adaptive function of repair of DNA damages. The first cytological demonstration of crossing over was performed by Harriet Creighton and Barbara McClintock in 1931. Their research and experiments on corn provided cytological evidence for the genetic theory that linked genes on paired chromosomes do in fact exchange places from one homolog to the other. The probability of chromosomal crossover occurring between two given points on the chromosome is related to the distance between the points. For an arbitrarily long distance, the probability of crossover is high enough that the inheritance of the genes is effectively uncorrelated. For genes that are closer together, however, the lower probability of crossover means that the genes demonstrate genetic linkage; alleles for the two genes tend to be inherited together.
Sources: en.wikipedia.org
=== Re–Ru === Lynne Regan (Ph.D. 1987). British biochemist and biotechnologist at the University of Edinburgh which studies interactions between proteins and nucleic acids. Jens Reich (b. 1939). German biophysicist at the Central Institute of Molecular Biology of the Academy of Sciences in Berlin-Buch, pioneer in systems biology. Founder of the New Forum (civil rights movement). Jacques Ricard (1929–2018). French biochemist at the Institut Jacques Monod known for studies of plant enzymes and for developing the concept of enzyme memory. David Rittenberg (1906–1970). American biochemist at Columbia, a pioneer in the use of radioactive tracers to study metabolism. Member Natl. Acad. Sci. USA. Alexander Rich (1924–2015). American biophysicist at MIT, whose many contributions included elucidation of the structure of collagen (with Francis Crick). Member Natl. Acad. Sci. USA. Jane S. Richardson (b. 1941). American biophysicist at Duke University, known for the ribbon diagram, a method of representing the 3D structures of proteins. Member Natl. Acad. Sci. USA. Thorburn Brailsford Robertson (1884–1930), Australian physiologist and biochemist, known for promoting the use of insulin for diabetes in Australia. Dame Carol V. Robinson (b. 1956), British chemist and mass spectroscopist at the University of Oxford known for studies of protein folding. Robert G. Roeder (b. 1942), American biochemist, pioneer in eukaryotic transcription. Irwin Rose (1926–2015). American biochemist at the University of Pennsylvania, noted for the discovery of ubiquitin-mediated protein degradation.
==== Enamel hypoplasia ==== Enamel hypoplasia refers to transverse furrows or pits that form in the enamel surface of teeth when the normal process of tooth growth stops, leaving a deficit. Enamel hypoplasias generally form due to disease and/or poor nutrition. Linear furrows are commonly referred to as linear enamel hypoplasias (LEHs); LEHs can range in size from microscopic to visible to the naked eye. By examining the spacing of perikymata grooves (horizontal growth lines), the duration of the stressor can be estimated, although Mays argued that the width of the hypoplasia bears only an indirect relationship to the duration of the stressor. Studies of dental enamel hypoplasia are used to study child health. Unlike bone, teeth are not remodeled, so intact enamel can provide a more reliable indicator of past health events. Dental hypoplasias provide an indicator of health status during the time in childhood when the enamel of the tooth crown is forming. The presence, frequency, and severity of enamel hypoplasia (EH) offer valuable information about general health conditions and the occurrence of disease or malnutrition. Elevated rates of EH are often interpreted as evidence of widespread physiological stress, such as famine, infectious disease outbreaks, or prolonged nutritional deficiencies. By comparing the prevalence of dental stress indicators across various groups such as different social classes, geographic regions, or time periods bioarcheologists can also infer disparities in living conditions, access to resources, and overall health.
=== As the OAM (1991–1998) === Joseph J. Jacobs was appointed the first director of the OAM in 1992. Jacobs' support for rigorous scientific methodology caused friction with Democrat U.S. Senator Tom Harkin and other OAM patrons. Harkin believed his allergies had been cured by bee pollen pills and expressed frustration with the "unbendable rules" of randomized clinical trials, saying, "it is not necessary for the scientific community to understand the process before the American public can benefit from these therapies." Harkin's office reportedly pressured the OAM to fund studies of favored theories, including the use of bee pollen and antineoplastons as treatments. OAM board member Barrie Cassileth publicly criticized the office as a purveyor of nonsense and described it as a "place where opinions are counted as equal to data". After Harkin appeared on television in 1994 with cancer patients who blamed Jacobs for blocking their access to antineoplastons, Jacobs resigned from the OAM in frustration. In an interview with Science, Jacobs criticized Harkin and other politicians for pressuring his office, promoting certain therapies, and, he says, attempting an end-run around objective science." Harkin drew support from Iowa Democrat Representative Berkley Bedell, who believed that cow colostrum had cured his Lyme disease. The OAM's budget grew in the 1990s. The office drew increasing criticism for its perceived lack of rigorous scientific study of alternative approaches favoring uncritical boosterism.
Sources: en.wikipedia.org
Neither of these ocular signs should be confused with exophthalmos (protrusion of the eyeball), which occurs specifically and uniquely in hyperthyroidism caused by Graves' disease (note that not all exophthalmos is caused by Graves' disease, but when present with hyperthyroidism is diagnostic of Graves' disease). This forward protrusion of the eyes is due to immune-mediated inflammation in the retro-orbital (eye socket) fat. Exophthalmos, when present, may exacerbate hyperthyroid lid-lag and stare.
Source: When tendons are injured, tendon cells are activated to promote repair, but this process can be slow. Recent research has focused on improving tendon healing through therapies such as stem cell injections, growth factors, and tissue-engineered approaches to enhance tendon cell activity and regeneration.
== Chemistry == Dexamethasone is a synthetic pregnane corticosteroid and derivative of cortisol (hydrocortisone) and is also known as 1-dehydro-9α-fluoro-16α-methylhydrocortisone or as 9α-fluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione. The molecular and crystal structure of dexamethasone has been determined by X-ray crystallography. It is a stereoisomer of betamethasone, the two compounds differing only in the spatial configuration of the methyl group at position 16 (see steroid nomenclature).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.